Acute Respiratory Distress Syndrome Market Report by Type (Diagnosis, and Treatment), End User (Hospitals, Specialty clinics, Home healthcare, and Others), Regions and Company Analysis 2024-2032

Global Acute Respiratory Distress Syndrome Market Analysis

The Acute Respiratory Distress Syndrome Market was US$ 1.23 Billion in 2023 and is projected to reach US$ 2.36 Billion by 2032, with a Compound Annual Growth Rate of 7.51% from 2024 to 2032.

Acute Respiratory Distress Syndrome is a medical condition where the lungs can't provide enough oxygen to vital organs. ARDS happens due to the accumulating of fluid in the alveoli, which stops the lungs from filling a sufficient amount of air and results in low oxygen reaching the direction of the bloodstream. It is mainly caused by other underlying causes like head, sepsis, inhalation of harmful substances, chest, pneumonia, and other injuries. The acute respiratory distress syndrome symptoms globally include low blood pressure, extreme tiredness, shortness of breath, and others. The ARDS is treated such as IV fluids, mechanical ventilation, and inhaled medication like nitric oxide. As per the WHO, 3 Million people worldwide are affected by ARDS each year. 

Promptly recognizing acute respiratory distress syndrome is crucial for initiating effective lung-protective ventilation strategies. Despite efforts to refine the disease definition, clinicians must quickly identify it. Diagnosis is often delayed, with reported under-diagnosis rates as high as 40%, though the likelihood of diagnosis increases with disease severity. Acute respiratory distress syndrome is characterized by various clinical criteria, none of which are exact. The current clinical criteria have low specificity, such as 63% for the Berlin definition in identifying diffuse alveolar damage (DAD) at autopsy. No biomarkers are available to assist in diagnosis, but active research in this area is ongoing.

The rising incidence of acute respiratory distress syndrome can be attributed to environmental pollutants like air pollution and toxin exposure, as well as chronic conditions such as heart disease, diabetes, and obesity. These factors elevate the risk of developing acute respiratory distress syndrome, primarily if the chronic conditions are poorly controlled. Additionally, the FDA-approved Beyfortus is used to prevent respiratory syncytial virus (SRV) lower respiratory tract disease in neonates and infants up to two years of age who remain vulnerable to severe RSV disease.

The impact of Acute Respiratory Distress Syndrome on healthcare systems worldwide. It mentions the increased admissions to critical care units and hospitals, with statistics from countries such as Australia, France, and the U.S. The text also emphasizes the significant percentage of ICU patients suffering from ARDS and the need for mechanical ventilation in children to manage acute respiratory failure.

The importance of increasing investment in healthcare for Acute Respiratory Distress Syndrome to improve patient outcomes and reduce the burden of potentially fatal conditions. It highlights the need for intensive medical intervention, including critical care support, research and development, advanced medical technologies, and mechanical ventilation. Additionally, it discusses the growth of healthcare infrastructure investment globally, with projections indicating significant increases in investment by 2025, particularly in the Middle East, Africa, and Asia.

United States Acute Respiratory Distress Syndrome Market

The United States leads the global market for Acute Respiratory Distress Syndrome due to its high prevalence rate. According to the WHO, 200,000 people in the United States are affected by ARDS every year, including both adults and children. The National Center for Biotechnology Information reports an ARDS incidence of 64 cases per 100,000 person-years in the United States, with up to 306 cases per 100,000 person-years in the 75–84 age group. Additionally, chronic lung diseases like asthma are a significant cause of ARDS, as asthma affects the airways in the lungs. According to the American Lung Association, over 34 million people in the U.S. live with chronic lung diseases like asthma and COPD. Asthma affects 26.8 million Americans, including 4.5 million children.

Global Acute Respiratory Distress Syndrome Company Analysis

Silence Therapeutics plc, Gilead Seiences Inc., Terumo Corporation, Getinge AB, Livanova Plc, Medtronic, Inc., Fresenius Se & Co. KGAA, Nipro, and Pfizer Inc. are prominent players in the worldwide Acute Respiratory Distress Syndrome Market.

Acute Respiratory Distress Syndrome Company New

• Jan 2024: LivaNova PLC will wind down its ACS Business Unit to focus on its core Cardiopulmonary and Neuromodulation Business Units. The wind-down is expected to be completed by the end of 2024.
• Feb 2024: Silence Therapeutics announced a $10 million milestone payment from AstraZeneca to initiate a phase 1 clinical trial of their siRNA collaboration.
• March 2024: Gilead Sciences, Inc. and Xilio Therapeutics, Inc. announced exclusive license agreements for Xilio's tumor-activated IL-12 program, XTX301.
• March 2024: Terumo Blood and Cell Technologies partnered with the CiRA Foundation to develop automated iPS cell manufacturing.
• March 2024: Getinge Announces U.S. Launch of Corin Operating Table and Ezea Surgical Light at AORN.
• March 2024: the FDA approved Medtronic's Evolut FX+ TAVR system for treating severe aortic stenosis. The system maintains the benefits of the legacy Evolut TAVR platform and facilitates coronary access.
• April 2024, Pfizer Inc. announced positive Phase 3 clinical trial results for ABRYSVO, a single-dose vaccine for adults 18 to 59 years old at risk of severe RSV-associated LRTD.
• In December 2022, Terumo Corp. and Kyowa Kirin Co. launched "G-Lasta Subcutaneous Injection 3.6 mg BodyPod" in Japan.

Type – Market is divided into 2 viewpoints

1.    Diagnosis
2.    Treatment 

End User – Market is divided into 4 viewpoints

1.    Hospitals
2.    Specialty clinics
3.    Home healthcare
4.    Others

Countries – Market is divided into 25 Country Acute Respiratory Distress Syndrome Industry

1.    North America

1.1    United States
1.2    Canada

2.    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherlands
2.8    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    United Arab Emirates
5.3    South Africa

Key Players: All key players have been covered from 4 points

1.    Overviews
2.    Recent Developments
3.    Product Portfolio
4.    Revenue

Company Analysis:

1.    Silence Therapeutics plc
2.    Gilead Seiences Inc.
3.    Terumo Corporation
4.    Getinge AB
5.    Livanova Plc
6.    Medtronic, Inc.
7.    Fresenius Se & Co. KGAA
8.    Nipro
9.    Pfizer Inc.

Report Details: